SYRE SPY003: Three-for-Three IBD Data, $7.7B Priced In

Spyre Therapeutics just became the only company on the market with clinical proof-of-concept for all three validated mechanisms in inflammatory bowel disease: alpha4beta7, TL1A, and IL-23. The stock trades at $85.69 with a $7.7 billion market cap, and the read the Street is applying is simple. Three targets, three Phase 2 wins, one combination platform. That read is only half right.

The monotherapy data is genuinely fine. It is not best-in-class, and anyone buying SYRE because SPY003 is “the next Skyrizi” is buying the wrong thesis. The actual thesis, the one that justifies $7.7 billion for a company with zero approved products, is the pairwise combination that reads out in 2027. Everything before that is noise.

The Platform Is the Product, Not the Antibodies

Spyre’s SKYLINE trial is a two-part platform study. Part A tested each of the three antibodies as a monotherapy in moderately-to-severely active ulcerative colitis. Part B, now enrolling, tests the pairwise combinations: SPY120 (alpha4beta7 plus TL1A), SPY130 (alpha4beta7 plus IL-23), and SPY230 (TL1A plus IL-23).

That is the bet. Nobody else is running a serious dual-mechanism IBD combination program at this scale, and the reason is obvious once you look at the biology. Alpha4beta7 blockade (the mechanism behind Takeda’s Entyvio) works on gut-homing lymphocytes. TL1A blockade (the target Merck paid $10.8 billion for when it bought Prometheus) attacks inflammation and fibrosis. IL-23 blockade (Skyrizi, Tremfya) hits the upstream cytokine cascade. Three different entry points into the same disease, and the combination of any two could deliver more than either alone.

If Part B shows that stacking mechanisms meaningfully beats monotherapy, Spyre has a category-defining asset. If it does not, the company is just a slower, later entrant into three crowded classes. There is no middle ground, and the market knows it. That binary is why the stock moved on a Phase 2 win that was broadly expected.

What the Three Readouts Actually Show

SPY003, the anti-IL-23 antibody, delivered the headline number this week: a 10.0-point reduction from baseline in the Robarts Histopathology Index (RHI) at Week 12, p less than 0.0001, among 44 patients, per the company’s September 8 release. Clinical remission by modified Mayo Score was 20%, endoscopic improvement 30%, and the modified Mayo change was negative 3.5. The company calls the RHI reduction “among the largest histologic improvements reported in UC trials,” and on that specific endpoint the claim holds. SPY001 posted a 9.2-point RHI reduction and SPY002 a 10.7-point reduction.

But here is the part the headline buries. On clinical remission, the endpoint that actually gets drugs approved and gets doctors to prescribe, SPY003’s 20% is the weakest of the three and only in line with the approved IL-23 class. Risankizumab’s INSPIRE trial reported 20.3% remission versus 6.2% placebo. Guselkumab’s QUASAR induction study reported 22.6% versus 7.9%. Spyre’s 20% sits right at that level, and with 41% of its patients having prior advanced-therapy exposure and a mean baseline modified Mayo of 6.9, this is not an easy population. The SPY001 result of 40% remission and SPY002’s 33% are the more interesting data points, because those two mechanisms have less crowded monotherapy fields.

The safety data is clean in the way that matters for a combination platform: 43% any adverse event, 11% severe, zero discontinuations, zero deaths across the SPY003 cohort. That tolerability is the whole game for combinations. You cannot stack two mechanisms if each one carries meaningful safety baggage. So far, Spyre can.

The Competitive Problem Spyre Is Walking Into

Spyre is not first to any of these mechanisms, and the field is accelerating behind it. Merck’s tulisokibart just posted the first-ever Phase 3 win for an anti-TL1A antibody in ulcerative colitis, hitting its primary Modified Mayo remission endpoint in ATLAS-UC. Merck paid $10.8 billion for Prometheus to get that asset, and it is now the clear TL1A leader. Teva and Sanofi’s duvakitug showed 47.8% clinical remission on the high dose in Phase 2b RELIEVE UCCD versus 20.45% placebo, and Roche’s afimkibart is in Phase 3. Spyre’s SPY002 TL1A is a credible fourth entrant in a race where the first three have deeper pockets and a head start.

On the IL-23 side, Spyre faces the exact same wall as every other late entrant: Skyrizi and Tremfya are already approved, already winning, and J&J’s oral IL-23 (icotrokinra) is coming up behind to compress the injectable market. SPY003’s 20% remission does not disrupt that.

That is precisely why the combination matters. Spyre cannot win a monotherapy war on any of these three targets. It is betting that the combination wins a war nobody else has fielded an army for yet. See the IBD catalyst roundup for how these threads fit together across the sector.

Valuation: Cheaper Than One TL1A Asset, but for a Reason

The cleanest comp is the one the market already drew. Merck paid $10.8 billion for Prometheus, a company whose entire value was a single TL1A antibody. Spyre, with three mechanisms, a combination platform, and a longer half-life engineering story, trades at $7.7 billion with roughly $1.15 billion in cash as of June 30, 2026, giving it an enterprise value around $6.5 billion. On that arithmetic, Spyre looks cheap: three shots on goal for less than Merck paid for one.

The catch is stage and proof. Prometheus’s tulisokibart had Phase 2 data that Merck validated with a Phase 3 win. Spyre’s three assets have Phase 2 monotherapy data and no Phase 3, no approved product, and no revenue. The $7.7 billion is not pricing “three Prometheuses.” It is pricing a call option on one thing: whether the Part B combination readout in 2027 shows additive efficacy. That is the entire re-rating case, and it is a binary.

Spyre also carries a second, quieter option: SPY072 in rheumatoid arthritis and psoriatic arthritis, with a SKYWAY readout in the fourth quarter of 2026. That is the next tradable catalyst before the big Part B readout, and it matters because it tests whether the platform extends beyond the gut. The RA leg is covered in more depth here.

Risks

The primary risk is that Part B shows additive toxicity without additive efficacy, or shows additive efficacy that is too modest to justify combination pricing and dosing complexity. The monotherapy remission rates, especially SPY003’s 20%, do not give much margin: if two 20%-ish mechanisms combine to 30%, that is a real drug. If they combine to 22%, Spyre is a $3 billion company, not a $7.7 billion one.

The second risk is time and dilution. With cash runway only into the second half of 2029 and a 2027 readout plus two more years of registrational work ahead, Spyre will likely raise again before any approval. The 2026 financing already added roughly 40% to the share count year over year, and that pattern does not stop until the balance sheet is proven.

The third risk is the TL1A horse race specifically. If Merck’s tulisokibart and duvakitug both reach market first with strong data, Spyre’s SPY002 combination leg gets squeezed on positioning even if the mechanism works.

Verdict

Spyre’s three-for-three proof-of-concept is a real milestone, and the combination thesis is differentiated. But at $7.7 billion, the stock is already pricing the dream outcome, not the base case, with the combo data still 18 months away.

Do not chase SYRE here. The position to take is a small one, one to two percent of a biotech portfolio, sized for the 2027 binary and with a hard stop if Part B disappoints. The stock re-rates toward $15 billion or more if the combination shows clear benefit over monotherapy. It falls toward $3 billion if it does not. That is a 2x up, 60% down profile, and it is only worth owning if you are willing to hold through the SKYWAY readout in late 2026 and the Part B data the year after. This is a platform call, not a drug call, and it is too early to be anything but small.